Results 201 to 210 of about 129,195 (289)

The use of intratumoral chemotherapy in an integumentary squamous cell carcinoma in a cockatiel (Nymphicus hollandicus) [PDF]

, 2013
Antonissen, Gunther, Croubels, Siska, De Cooman, Lien, Ducatelle, Richard, Garmyn, An, Hellebuyck, Tom, Martel, An, Van de Maele, Isabel   +7 more
core  

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1457-1472, May 2026.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Idris Bahce, Medhat M. Said, Jan Buter, Harmen Huls, Paolo Magni, Imke Bartelink   +10 more
wiley   +1 more source

NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum. [PDF]

EMBO Mol Med
Bernardo S, Brunet L, Thomas QD, Bracquemond D, Bouclier C, Colomb M, Mancini M, Fabbrizio E, Santos A, Rasamizafy SF, Maacha AM, Giry A, Bousquet-Mur E, Papon L, Goussard M, Fremin C, Pasquier A, Rodríguez M, Travert C, Pujol JL, Linares LK, Heron-Milhavet L, Djiane A, Ferrer I, Paz-Ares L, Quantin X, Montuenga LM, Tourriere H, Maraver A.   +28 more
europepmc   +1 more source

Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta‐Analysis

Brain and Behavior, Volume 16, Issue 5, May 2026.
This study is a systematic review and meta‐analysis comparing bevacizumab‐, temozolomide‐, and lomustine‐based treatments for recurrent glioblastoma. The findings suggest that monotherapy, particularly bevacizumab, may provide better clinical outcomes with fewer adverse events than combination regimens. ABSTRACT Background Glioblastoma multiforme (GBM)
Kayode Agboola, Fatemeh Khafaji, Bipin Chaurasia, Kashif Qureshi, Kivanc Yangi, Vishal Chavda, Naci Balak   +6 more
wiley   +1 more source

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. [PDF]

Gynecol Oncol Rep
Francoeur AA, Liang SY, File B, Choi E, Brameld M, Richardson MT, Johnson CR, Kapp DS, Tewari KS, Chan JK.   +9 more
europepmc   +1 more source

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley   +1 more source

Impact of Physical Frailty on Early Intolerance to CAPOX Chemotherapy in Patients With Colon, Rectal, and Gastric Cancer

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Patients with gastrointestinal cancer often present reduction in functional capacity and develop frailty, which increases the risk of chemotherapy intolerance. We investigated whether physical frailty is associated with early intolerance to CAPOX (capecitabine+oxaliplatin) in patients with colon, rectal, or gastric cancer.
Isabella Pellegrini Grama Pereira Lima, Nicolle Martins Carrozzi, Talita Oliveira Silva, Karina Almeida de Brunheroti, Joyce Lucchesi, Andréia Cristina Dalbello Rissati, Lucinea Valério de Almeida Castro, Maria Carolina Santos Mendes, José Barreto Campello Carvalheira, Lígia M. Antunes‐Correa   +9 more
wiley   +1 more source

Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience. [PDF]

J Natl Cancer Inst
Sousa LG, Edward Bates J, Anand P, Caudell JJ, Colevas AD, Runge CL, Sharon JD, Awan M, Beadle BM, Choe JH, Gidley PW, Harari PM, Henson C, Katzel JA, Lee NY, McDowell L, Mell LK, Nader ME, Rudra S, Wang K, Yang G, Yom SS, Wise-Draper TM.   +22 more
europepmc   +1 more source

Neoadjuvant Immunochemotherapy Increases the Abundance of Tertiary Lymphoid Structures and Lymphocyte Subpopulations Is Associated With Prognosis of Esophageal Squamous Cell Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Neoadjuvant immunochemotherapy (NIC) has emerged as a promising strategy for esophageal squamous cell carcinoma (ESCC). However, its impact on tertiary lymphoid structures (TLSs) and the immune microenvironment remains to be fully elucidated. We retrospectively analyzed 50 ESCC patients treated with NIC (n = 25) or chemotherapy alone (n = 25 ...
Ning Li, Xiaoyan Zhang, Xupeng Tang, Juanning Shen, Qing Qi, Huili Wu, Yuze Zhao, Shuo Wang   +7 more
wiley   +1 more source

Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer. [PDF]

J Exp Clin Cancer Res
Altman JE, Valentine A, Dashti-Gibson N, Zboril EK, Boyd DC, Myrick RK, Olex AL, Dozmorov MG, Harrell JC.   +8 more
europepmc   +1 more source